Literature DB >> 11021604

Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use.

S Gnagy1, E E Ming, S S Devesa, P Hartge, A S Whittemore.   

Abstract

Ovarian cancer incidence and mortality rates have declined among U.S. women age 35-59 years during the period 1970-1995. Epidemiologic studies have shown that ovarian cancer risk decreases with increasing parity and increasing duration of oral contraceptive use. During this period, parity has declined while oral contraceptive use has increased. We compared temporal trends in observed ovarian cancer incidence rates with rates predicted by changes in parity and duration of oral contraceptive use to determine whether the changes in these characteristics could explain the declining rates in younger women. In addition, we wished to examine whether oral contraceptive use continues to be protective to postmenopausal women. To predict changes in rates between 1970 and 1995, we assumed that increases in parity and duration of oral contraceptive use induce proportional decreases in incidence rates. We found that the rates predicted by these assumptions agreed well with observed rates in young women (age 30-49) but were substantially lower than observed rates in older women (age 50-64). The data indicate that the relative decrease in incidence rates due to the protective effect of oral contraceptive use declines with age.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021604     DOI: 10.1097/00001648-200003000-00004

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  9 in total

1.  Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States.

Authors:  Hannah P Yang; William F Anderson; Philip S Rosenberg; Britton Trabert; Gretchen L Gierach; Nicolas Wentzensen; Kathleen A Cronin; Mark E Sherman
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

2.  Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes.

Authors:  Hyo K Park; Julie J Ruterbusch; Michele L Cote
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-27       Impact factor: 4.254

3.  Effect of luteinizing hormone-induced prohibitin and matrix metalloproteinases on ovarian epithelial tumor cell proliferation.

Authors:  Yue Wang; Hong Liao; Holly C Zheng; Linmin Li; Lin Jia; Zhengbo Zhang; Wenxin Zheng
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

4.  Luteinizing hormone compromises the in vivo anti-tumor effect of cisplatin on human epithelial ovarian cancer cells.

Authors:  Yan Huang; Yuqi Zhou; Lingfang Xia; Jia Tang; Hao Wen; Meiqin Zhang
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

5.  Lifetime number of ovulatory cycles and epithelial ovarian cancer risk in African American women.

Authors:  Lauren C Peres; Patricia G Moorman; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Edward S Peters; Ann G Schwartz; Paul D Terry; Sarah E Abbott; Fabian Camacho; Frances Wang; Joellen M Schildkraut
Journal:  Cancer Causes Control       Date:  2017-03-02       Impact factor: 2.506

6.  International patterns and trends in ovarian cancer incidence, overall and by histologic subtype.

Authors:  S B Coburn; F Bray; M E Sherman; B Trabert
Journal:  Int J Cancer       Date:  2017-03-21       Impact factor: 7.396

7.  Declining second primary ovarian cancer after first primary breast cancer.

Authors:  Sara J Schonfeld; Amy Berrington de Gonzalez; Kala Visvanathan; Ruth M Pfeiffer; William F Anderson
Journal:  J Clin Oncol       Date:  2013-01-02       Impact factor: 44.544

8.  Intrauterine device use and risk of ovarian cancer: Results from the New England Case-Control study and Nurses' Health Studies.

Authors:  Jiaxi Yang; Naoko Sasamoto; Ana Babic; Allison F Vitonis; Mary K Townsend; Linda Titus; Daniel W Cramer; Shelley S Tworoger; Kathryn L Terry
Journal:  Int J Cancer       Date:  2021-03-17       Impact factor: 7.316

9.  Incessant ovulation and ovarian cancer - a hypothesis re-visited.

Authors:  M F Fathalla
Journal:  Facts Views Vis Obgyn       Date:  2013
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.